Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: SUN13834
Drug: Placebo

First Posted Date: 2008-07-17

Last Posted Date: 2021-04-21

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 270

Registration Number: NCT00717769

Locations: 🇺🇸
Radiant Research, Inc., Birmingham, Alabama, United States
🇺🇸
Pivotal Research Center, Peoria, Arizona, United States
🇺🇸
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States

and more 24 locations

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Cachexia

Interventions: Drug: SUN11031 20 μg/kg
Drug: SUN11031 40 μg/kg
Drug: Placebo comparator

First Posted Date: 2008-06-17

Last Posted Date: 2021-01-28

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 227

Registration Number: NCT00698828

Locations: 🇺🇸
Waterbury Pulmonary Associates, Waterbury, Connecticut, United States
🇺🇸
Clinical Research of West Florida, Clearwater, Florida, United States
🇺🇸
Innovative Research of West Florida, Largo, Florida, United States

and more 39 locations

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

Phase 4

Completed

Conditions: Type 2 Diabetes
Hypertension

Interventions: Drug: Amlodipine
Drug: amlodipine / olmesartan medoxomil combination
Drug: Hydrochlorothiazide

First Posted Date: 2008-04-09

Last Posted Date: 2010-07-13

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 207

Registration Number: NCT00654745

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Olmesartan medoxomil
Drug: Amlodipine
Drug: Hydrochlorothiazide

First Posted Date: 2008-04-01

Last Posted Date: 2019-01-09

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 2500

Registration Number: NCT00649389

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: piclozotan
Drug: 0.9% sodium chloride (normal saline)

First Posted Date: 2008-02-26

Last Posted Date: 2021-03-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 27

Registration Number: NCT00623363

Locations: 🇺🇸
The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸
University of South Florida, Parkinson's Disease and Movement Disorders Center, Tampa, Florida, United States
🇺🇸
Emory University--Wesley Woods Health Center, Atlanta, Georgia, United States

and more 4 locations

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: CS-0777 tablets

First Posted Date: 2008-02-15

Last Posted Date: 2011-03-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 25

Registration Number: NCT00616733

Effects of CS-8080 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CS8080
Drug: Placebo

First Posted Date: 2008-02-13

Last Posted Date: 2018-12-21

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 72

Registration Number: NCT00613431

Locations: 🇺🇸
MDS Pharma Services, Neptune, New Jersey, United States

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1

Terminated

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: CS-7017
Drug: Paclitaxel

First Posted Date: 2008-01-29

Last Posted Date: 2020-09-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 19

Registration Number: NCT00603941

Locations: 🇺🇸
Univ of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: pioglitazone HCl
Drug: rivoglitazone HCl
Drug: placebo
Drug: pioglitazone HCl 45 mg
Drug: metformin

First Posted Date: 2007-12-12

Last Posted Date: 2021-05-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 94

Registration Number: NCT00571519

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus
Hypercholesterolemia
Pre-diabetes

Interventions: Drug: Colesevelam placebo
Drug: Metformin HCl tablets and Colesevelam tablets
Drug: Metformin HCl and Colesevelam Placebo
Drug: Colesevelam

First Posted Date: 2007-12-11

Last Posted Date: 2010-07-27

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 502

Registration Number: NCT00570739

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy